NCT03291990View on ClinicalTrials.gov

5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Temozolomide

5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide

Trial Locations (3)

20016

Sibley Hospital, Washington D.C.

20818

Suburban Hospital, Washington D.C.

21287

SKCCC at Johns Hopkins (East Baltimore), Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03291990 - 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter